Thymosin Alpha-1
Thymosin Alpha-1 is a 28-amino-acid peptide naturally produced by the thymus gland. It has been extensively studied for immune support with over 70 clinical trials. Research covers hepatitis treatment, cancer immune therapy, and sepsis management.
Verified sources for Thymosin Alpha-1
These vendors are vetted by PeptideWiki for purity testing and COA transparency.
Overview of Thymosin Alpha-1
Modulates immune function through Toll-like receptor pathways, enhancing T-cell maturation, dendritic cell activation, and cytokine balance.
Activates TLR2, TLR5, and TLR9 on dendritic cells, triggering downstream signaling cascades controlling inflammation, immunity, and tolerance.
Promotes differentiation of T-cell progenitors into mature CD4+ and CD8+ T cells, restoring cell-mediated immunity in immunocompromised states.
Balances pro- and anti-inflammatory cytokine production, increasing IL-2, IFN-γ, IFN-α while modulating TNF-α and IL-6.
Enhances antigen presentation through myeloid and plasmacytoid dendritic cell activation, improving adaptive immune responses.
Used in sepsis, chronic hepatitis B/C, HIV immune reconstitution, with extensive clinical trial data available.
Cancer immunotherapy support and vaccine adjuvant applications (proposed), which may enhance immune responses to treatments
Read Full Thymosin Alpha-1 Dosage Guide
Research-backed dosing protocols, timing, and administration details
Browse more in this category
Immune & Inflammation
RFK Jr. Says 14 Peptides Are Coming Back: Ban Reversal
HHS Secretary RFK Jr. told Joe Rogan that ~14 peptides banned by the FDA in 2023 will return to Category 1, restoring legal compounding access.
FDA Peptide Ban: What 75,000 Patients Reveal About Safety
Brigham Buhler treated 75,000 patients with peptides and reported zero adverse events. So why did the FDA restrict them from compounding pharmacies? The real reasons may surprise you.